Advertisement

Topics

Grid Therapeutics Signs Exclusive License Agreement to Develop a Novel Immuno-Oncology Antibody

07:07 EDT 22 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Grid Therapeutics, LLC, an oncology-focused biotechnology company announced the execution of an exclusive license agreement with Duke University to develop the first human derived antibody as a targeted immunotherapy for ...

Other Sources for this Article

Grid Therapeutics, LLC
Scott Lyman, 919-987-7190
Chief Business Officer

NEXT ARTICLE

More From BioPortfolio on "Grid Therapeutics Signs Exclusive License Agreement to Develop a Novel Immuno-Oncology Antibody"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...